Evidence map›Paper›PMID 40302212›Full record

Trial reportActa obstetricia et gynecologica Scandinavica2025

Magnetic resonance guided high intensity focused ultrasound (MR-HIFU) effectively reduces fibroid-related symptoms and improves quality of life-A prospective single-centre 12-month follow-up study.

Saara Otonkoski, Antti Viitala, Gaber Komar, Teija Sainio, Anna Yanovskiy, Roberto Blanco Sequieros, Antti Perheentupa, Kirsi Joronen

Registry-linked trialAbstract readClinical Trial, Phase IV
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Acta obstetricia et gynecologica Scandinavica, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03937401 (Use of Oxytocin in MRI-HIFU Treatment), which is not on this map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03937401 phase4unknown statusnot on this map

Use of Oxytocin in MRI-HIFU Treatment

TypeinterventionalSponsorTurku University HospitalRan2019 to 2021Enrolled100ConditionsFibroid, AdenomyosisArmsOxytocin
3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Changes in symptoms and fibroid characteristics in women treated with ultrasound-guided high intensity focused ultrasound (USgHIFU) at Chris Hani Baragwanath Academic Hospital.International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics · 2026
    Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Saara OtonkoskiDepartment of Obstetrics and Gynaecology, Turku University Hospital, Turku, Finland.ORCID https://orcid.org/0000-0002-7873-1204
Antti ViitalaUniversity of Turku, Turku, Finland.
Gaber KomarUniversity of Turku, Turku, Finland.
Teija SainioUniversity of Turku, Turku, Finland.
Anna YanovskiyUniversity of Turku, Turku, Finland.
Roberto Blanco SequierosUniversity of Turku, Turku, Finland.
Antti PerheentupaDepartment of Obstetrics and Gynaecology, Turku University Hospital, Turku, Finland.ORCID https://orcid.org/0000-0002-1413-6414
Kirsi JoronenDepartment of Obstetrics and Gynaecology, Turku University Hospital, Turku, Finland.ORCID https://orcid.org/0000-0002-5527-8371

Funding

Finnish Government Research Funding
6 · The paper itself

Abstract

introductionUterine fibroids are the most common benign tumors among women, and it is estimated that approximately 70% of women have one or multiple fibroids by the age of menopause. About 30% of these women suffer from symptoms related to the fibroids. Magnetic resonance-guided high-intensity focused ultrasound (MR-HIFU) is a novel, non-invasive treatment method for symptomatic uterine fibroids. MATERIAL AND

methodsIn this prospective, single-centre follow-up study, 175 women with symptomatic uterine fibroids were treated with MR-HIFU. The effect of MR-HIFU on fibroid symptoms and quality of life was evaluated using a uterine fibroid-specific quality of life questionnaire (UFS-QoL). The main outcome measure was the symptom severity score and quality of life (QoL) before the MR-HIFU and 3 and 12 months after the treatment. This study was registered at clinicaltrials.gov (NCT03937401).

resultsThe median symptom severity score decreased from 56 (IQR 44-69) at baseline to 28 (IQR 16-44) at 3 months (p < 0.01) and 25 (IQR 16-38) at 12 months (p < 0.01) after treatment. The QoL score increased from a median of 48 (IQR 33-66) at baseline to 73 (IQR 59-93) at 3 months (p < 0.01) and 78 (IQR 66-90) at 12 months after treatment (p < 0.01). The reintervention rate during the 12-month follow-up was 2%.

conclusionsMR-HIFU significantly reduces the severity of fibroid-related symptoms in selected patients as early as 3 months after MR-HIFU. The effect persists at 12 months. There is also a significant improvement in the quality of life 3 months after treatment, which further increases at 12 months.

Indexed as

High-Intensity Focused Ultrasound AblationLeiomyomaQuality of LifeUterine NeoplasmsAdultFemaleFollow-Up StudiesHumansMagnetic Resonance ImagingMiddle AgedProspective StudiesTreatment OutcomefibroidMR‐HIFUquality of lifeuterine fibroid

Identifiers

PMID40302212
PMCPMC12087502

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.